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A B S T R A C T
Vindoline, an indole alkaloid present in the leaves of Catharanthus roseus plant, has been recently reported to
have insulotropic effects. This present study evaluated the possible hepatoprotective effects of vindoline in a type
2 diabetes mellitus rat model. Diabetes mellitus was induced by exposing rats to 10% fructose water for two
weeks followed by a single intraperitoneal injection of 40mg/kg body weight of streptozotocin (STZ). Rats were
randomly divided into six groups (n=8) and treated daily for 6 weeks with the vehicle via oral gavage, vin-
doline (20mg/kg) or glibenclamide (5mg/kg). Weekly fasting blood glucose (FBG) levels and body weight were
measured and recorded. Administration of vindoline significantly (p < 0.05) reduced FBG by 15% when
compared to the diabetic controls. Vindoline significantly (p < 0.05) decreased diabetes-induced hepatic injury
shown by decreased levels of serum alanine transferase (ALT) (-42%), aspartate aminotransferase (AST) (-42%)
and alkaline phosphatase (-62%) compared to the diabetic controls. The oxygen radical absorbance capacity and
the activities of superoxide dismutase (SOD) and catalase (CAT) were also improved following treatment with
vindoline. The results also showed decreased levels of pro-inflammatory cytokines such as TNF-ɑ by (-41%) and
IL-6 (-28%) which may have also contributed to the reduction of serum triglycerides (-65%) in the diabetic group
treated with vindoline. Histopathological findings showed improvement of both the hepatic and pancreatic
tissues following vindoline treatment. Overall, these findings suggest that vindoline may protect the diabetic
hepatic tissue from injury via antioxidant, anti-inflammatory and anti-hypertriglyceredemia mechanisms
thereby retarding the development of diabetic complications.
1. Introduction
Diabetes mellitus (DM) has recently been labelled as one of the
chronic diseases that has become a global health threat [1]. According
to the World Health Organisation (WHO) 2016 report [2], an estimate
of 422 million people globally were diagnosed with DM in 2014 while a
108 million had diabetes in 1980. DM is also one of the four most
common non-communicable-diseases and currently the seventh leading
cause of morbidity and mortality globally [3]. This high mortality rate
is associated with complications such as diabetic liver disease (DLD)
which progressively develop in these patients. Liver cirrhosis, steato-
hepatitis, non-alcoholic fatty liver disease (NAFLD) and hepatic carci-
nomas are examples of different spectrums of DLDs that are observed in
T2DM patients with persistent hyperglycaemia [4,5]. DLDs primarily
develop as a consequence of hyperglycaemia, hypertriglyceridemia and
insulin resistance. In the absence of sufficient cytoprotective molecules,
these cofactors induce inflammation, oxidative damage and finally
necrosis or apoptosis [5,6]. In diabetes, chronic hyperglycaemia pro-
vides an environment that facilitates free radical formation, con-
comitantly depleting the endogenous antioxidant reserves ultimately
leading to oxidative tissue damage [7,8]. Additionally, increased levels
of free radicals activate pro-inflammatory cytokines and the transcrip-
tion of pro-apoptotic genes thus mediating chronic inflammatory re-
sponses and hepatocyte death respectively [9]. Abnormal high glucose
levels have the ability to induce apoptosis by activating Bax–caspase
proteases that alter mitochondrial function leading to apoptosis [10].
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Therapeutic strategies which can efficiently prevent or reverse the ad-
verse effects of prolonged oxidative stress and inflammation in DM may
be highly beneficial in preventing diabetic complications such as DLDs.
From past decades, concerted efforts were made in attempts to
manage diabetes. These efforts evoked the discovery of different or-
thodox drugs currently used to achieve better glycaemic control and
thus prevention of DM complications. A major drawback of oral anti-
diabetic agents is their failure to effectively cure diabetes; moreover,
they have been associated with increased side effects [11]. In this re-
gard, medicinal plants appear as promising therapeutic avenues moti-
vated by the presence of phytoconstituents that have numerous health
benefits and may act as precursors in drug formulations [12–14].
Catharanthus roseus or Vinca rosea is a medicinal plant that has its
origin in Madagascar hence the other name Madagascar periwinkle
[15–18]. Traditionally, it was used to treat diseases like cancer, ma-
laria, diabetes, insomnia and high blood pressure [18–21]. Different
scientific studies reported the anti-hyperglycaemic nature of different
extracts of C. roseus attributed to the presence of indole alkaloids, fla-
vonoids, beta sitosterol, quercetin, catharanine [17,22–26]. Vindoline
is an indole alkaloid extracted from C.roseus which was recently been
reported to possess protein-tyrosine phosphatase 1B (PTP-1B) in-
hibitory effects and therefore may serve as an “insulin sensitizer” in the
management of T2DM [18,21]. To the best of our knowledge there is
limited knowledge/information on the effects of vindoline in T2DM and
associated complications. The present study was undertaken to evaluate
the effect/s of vindoline against hyperglycaemia-induced oxidative
tissue damage in the liver of T2DM- induced male Wistar rats.
2. Materials and methods
2.1. Animal care
Six weeks old male Wistar Rats were purchased from Charles River
(Margate United Kingdom). Animals were housed at the South African
Medical Research Council (PUDAC) according to the national standards
and policies set out in the South African National Standard for the Care
and Use of Animals for Scientific Purposes (South African Bureau of
Standards SANS (10386:2008). Six rats per cage were housed under
controlled standard environmental conditions (23 ± 1 °C, 55 ± 5%
humidity, 12:12 h cycles of light to darkness. All the rats had free access
to water and standard laboratory diet called Standard Rat Chow (SRC).
2.2. Ethical approval
This study was granted approval from the Ethics Committee for
Research on Animals of the South African Medical Research Council
(REF-01/17) and from the Faculty of Health and Wellness Research
Ethics Committee of Cape Peninsula University of Technology, South
Africa (CPUT/HW-REC 2016/A4).
2.3. Plant-derived chemical and standard drug
Vindoline was purchased from the manufacturer: Best of Chemicals
(BOC) Sciences, USA). Specific guidelines, storage and preparation
methods were followed as per suppliers’ instructions. The standard drug
glibenclamide was purchased from a local pharmacy and used in the
experiment.
2.4. Induction of T2DM
T2DM was induced in rats by having them drink 10% fructose so-
lution ad libitum for 14 days. Non-diabetic rats only drank normal tap
water ad libitum. On day 15, rats received a single intraperitoneal in-
jection of low dose of streptozotocin (STZ, 40mg/kg body weight
(b.w)) in freshly prepared 0.1M citrate buffer (pH 4.5) after an over-
night fast. Diabetes was confirmed 72 h post STZ administration, rats
with 4 h fasting blood glucose level; between 15mmol/ and 40mmol/l
were considered diabetic. Daily treatment (for 6 weeks) through oral
gavage with respective compounds (vindoline/ glibenclamide) com-
menced after 5 days of STZ administration to ensure stable hypergly-
caemia.
2.5. Experimental design
Forty-eight (48), 6 weeks old male Wistar rats (190–230 g) were
randomly divided into six (6) groups with a minimum of eight rats each
(n= 8). Rats in all the groups were fed ad libitum with standard rat
chow (SRC) and tap water.
Group N: normal control administered with vehicle only;
Group NV: normal treated group administered with vindoline
(20mg/kg b.w);
Group NG: normal treated group treated with glibenclamide (5mg/
kg b.w).
Group DC: diabetic control group administered with vehicle;
Group DV: diabetic treated with 20mg/kg b.w of vindoline;
Group DM: diabetic treated with 5mg/kg b.w of glibenclamide;
Fasting blood glucose levels and weights were measured once a
week using a glucometer and a balance respectively while blood sam-
ples were collected via the tail prick. After the 8 week study period, the
rats were fasted overnight in preparation for sacrifice and sample col-
lection. Final blood glucose levels and body weights were recorded
prior to termination of experiment. Rats were anaesthetised and eu-
thanized using isoflurane gas at 2% with 1% oxygen during laparotomy.
2.6. Serum preparation
Blood samples were collected from the abdominal vena cava into
10ml serum separator vacutainer tubes (yellow top tubes). Tubes were
allowed to stand at room temperature for 30min prior to centrifuga-
tion. The samples were centrifuged at 3500 rpm for 15min. Once cen-
trifuged, the serum and plasma were aliquoted into cryo-tubes, snap-
frozen in liquid nitrogen and stored at −80 °C.
2.7. Organ preparation
Liver samples were collected, quickly washed in phosphate buffered
saline (PBS) to remove blood and then weighed. Some portions to be
used for antioxidant analysis were snap frozen in liquid nitrogen and
stored at −80 °C for future analysis. Remaining portions were pre-
served in 10% (v/v) neutral buffered formalin and embedded in par-
affin wax for histological analysis. Later on, the snap frozen samples
were homogenised in ice-cold respective buffers for different en-
dogenous antioxidant activity determination. Homogenates were cen-
trifuged for 15min at 15,000 rpm at 4 °C, aliquoted and stored at
−80 °C until analysis.
2.8. Determination of the relative liver weights
The relative liver weights were calculated using the following for-
mula
Relative liver weight = (liver weight ÷ total body weight) 100g
2.9. Liver function enzymes activity
The activities of aspartate amino transferase (AST), alanine amino
transferase (ALT), alkaline phosphatase (ALP) and lactate dehy-
drogenase (LDH) were measured using ABX PENTRA 400 automated
chemistry analyser machine.
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2.10. Measurement of hepatic antioxidant marker enzymes and reduced
GSH level
Catalase (CAT) activity was determined spectrophotometrically by
assessing the exponential disappearance of H2O2 at 240 nm. The assay
was carried out according to the method of Aebi [27]. The activity of
superoxide dismutase (SOD) was measured following the procedure
described by Crosti et al [28]. The level of reduced glutathione (GSH)
was determined by the method of Jollow et al [29] and measured
spectrophotometrically at 412 nm.
2.11. Determination of lipid peroxidation
Lipid peroxidation (LPO) in the liver homogenates was assessed by
measuring the amount of malondialdehyde (MDA) products that were
reacted with the thiobarbituric acid. The coloured complex formed
when MDA reacted with thiobarbituric acid (TBA) was measured at
532 nm according to the method used by Tug et al [30].
2.12. Hepatic antioxidant analysis
Oxygen radical absorbance capacity (ORAC) is an assay that mea-
sures the ability of antioxidants in a particular sample to scavenge ra-
dicals [31]. The principle of the assay is based on the scavenging and
inhibition capacity of lipophilic antioxidants in the presence of a cy-
clodextrin water-based enhancer upon the free radical damages. The
free radical damage is evaluated by the loss of fluorescence of a fluor-
escent probe over time; therefore the decrease of fluorescence signifies
the extent of free radical damage and as well as a direct proportional
relationship with the free radical concentration [31,32].
2.13. Measurement of triglycerides
The concentration of triglycerides in the serum was determined
using the ABX PENTRA 400 chemistry analyser. The kit was purchased
from Scientific Group Company (South Africa).
2.14. Inflammatory cytokines
The amount of cytokines: interleukin-6 (IL-6), IL-10, IL-1b and
tumor necrosis factor (TNF)-ɑ in the homogenates were evaluated using
the Bio-plex® platform (Bio-rad Laboratories, Hercules, CA (USA). The
MILLIPLEX® MAP rat cytokine magnetic bead-based Luminex kit was
purchased from Merck Millipore, Billerica, MA (USA).
2.15. Histopathological studies
Washed liver samples were fixed in 10% formalin, processed using
routine histology techniques. The liver samples were then embedded in
paraffin and were cut into sections of 5 μm thickness using the Leica
RM2125 microtome (Leica Microsystems, Inc., Buffalo Grove, United
States of America). The sections were deparaffinised and stained using
haematoxylin and eosin (H & E) stain
2.16. Immunohistochemistry
Anti-Bcl2, anti-caspase 3 and anti-caspase 9 antibodies were ob-
tained from Abcam. Formalin-fixed, paraffin-embedded liver sections
were first pre-treated with heat-induced epitope retrieval (HIER) for
20min at 98 °C so as to expose antigen sites. Respective antibodies at a
dilution of 1:100 were added to the slides. Immuno labelling staining
was performed using the Leica Bond autostainer (Leica Biosystems, SA).
Slides were incubated with peroxidase block for 5min using the Bond
Polymer Refine Detection Kit. The sections were then incubated for
30min in respective primary antibodies. Following incubation, post
primary block incubation using post primary antibody was performed
at room temperature for 30min. Incubation of slides with 3,3′
Diaminobenzidine (DAB) chromogen solution and DAB substrate buffer
polymer was done to facilitate the production of a brown end-product.
Finally, hematoxylin was used to counterstain the nuclei during a 5min
incubation step. Liver tissue sections were dehydrated by moving slides
in a series of graded alcohols. Slides were finally mounted using dibutyl
phthalate xylene (DPX). Slides were viewed and images captured using
the EVOS XL Cell imaging microscope. Positive intensities were ana-
lysed and quantified using ImageJ Immuno Profiler software (version
10.2 image analysis).
2.17. Statistical analysis
Results were analysed using GRAPH PAD Prism software package,
Version 5.0. Data were expressed as mean ± standard error mean
(SEM). The comparisons within groups were determined by using the
one way analysis of variance (ANOVA) and Bonferonni’s multiple test
comparison. The values were considered to be statistically significant
when the p value was<0.05.
3. Results
3.1. Effect of vindoline or glibenclamide on body weight, liver weight and
blood glucose levels
The effect of vindoline or glibenclamide administration on blood
glucose, serum insulin, and body and liver weights in T2DM-induced
and normal rats is represented in Table1 below. Treating diabetic rats
with vindoline resulted in significant decrease in blood glucose level
(15% decrease) in comparison with the diabetic control (DC)
(p < 0.05) whereas glibenclamide did not show significant alterations
in glucose levels when its effect on glucose levels was compared to both
the diabetic controls as well as the diabetic group that received vin-
doline (p > 0.05). In normal rats, vindoline and glibenclamide caused
no major changes in the glucose levels when compared to the normal
controls. The insulin level in diabetic rats treated with vindoline (DV)
Table 1
Effect of vindoline or glibenclamide administration on glucose, serum isulin, body and liver weights in T2DM-induced and normal rats.
Parameters NC NV NG DC DV DG
FG (mmo/L 10.62 ± 0.34b 10.04 ± 0.31b 10.18 ± 0.29b 31.94 ± 0.54a 27.15 ± 1.47ab 29.23 ± 1.33a
Insulin μlU/ml 11.67 ± 1.03 7.43 ± 0.37a 9.85 ± 0.92b 5.13 ± 0.46a 9.56 ± 1.32b 8.47 ± 1.09
FBW(g) 293.1 ± 23.34b 338.4 ± 37.05ab 310.0 ± 29.45b 243.1 ± 33.6 241.0 ± 26.64a 255.8 ± 15.80
WC (%) 94.56 83.0b 79.51b 31.21a 46.06a 52.339a
LW (g) 9.71 ± 1.18 11.31 ± 1.67 9.46 ± 1.07 11.97 ± 1.04 11.04 ± 1.54 12.02 ± 1.02
RLW (g) 3.32 ± 0.38b 3.34 ± 0.27b 3.05 ± 0.1b 4.97 ± 0.51 4.59 ± 0.48a 4.70 ± 0.28a
Data represented as means ± SEM. FG: final blood glucose; FBW: final body weight; WC: percentage weight change; LW: liver weight; RLW: relative liver weight. a
p < 0.05 vs normal control. b p < 0.05 vs diabetic control. C p < 0.05 vs normal rats treated with vindoline. d p < 0.05 vs normal rats treated with glibenclamide.
NC: normal control; NV: normal control treated with vindoline; NG: normal control treated with glibenclamide; DC: diabetic control; DV: diabetic treated with
vindoline; DG: diabetic treated with glibenclamide.
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was elevated significantly (p < 0.05) in comparison to the diabetic
controls. However, we did not observe any substantial differences in
insulin levels between the diabetic-glibenclamide group and diabetic
controls and diabetic rats treated with vindoline. Neither the percen-
tage body weight change nor the liver weights (expressed as relative
liver weights) were significantly modified by vindoline treatment in the
diabetic and normal groups when compared to the diabetic controls and
the normal untreated group respectively.
3.2. Effects of Vindoline or glibenclamide on serum levels of hepatic
enzymes (hepatic function) in T2DM-induced rats
Table 2 illustrates the effects of vindoline or glibenclamide on the
activities of liver enzymes (liver function). Induction of T2DM in rats
especially the diabetic controls resulted in substantial elevation of
serum liver function enzymes (AST, ALT, ALP and LDH) when com-
pared to the non-diabetic groups. Interestingly, vindoline and glib-
enclamide attenuated the levels of AST, ALT and ALP in diabetic rats in
comparison with the diabetic control group (p < 0.05) but LDH re-
mained unaltered. Normal rats that received vindoline showed mar-
ginally elevated AST levels when compared to the normal controls and
normal rats treated with glibenclamide.
The levels of total protein (TP) and albumin in the diabetic controls
were significantly higher than the diabetic group treated with glib-
enclamide (p < 0.05). Vindoline did not significantly modify the levels
of TP and albumin in T2DM rats when compared to the diabetic con-
trols or the diabetic group. Normal rats treated with vindoline showed
significantly increased TP (P < 0.05) when compared to all the groups.
3.3. Antioxidant activity of liver homogenates
Presented in Fig. 1 is the hepatic antioxidant status of non-diabetic
and diabetic rats. After administration of vindoline and glibenclamide
in T2DM, there was a significant improvement of ORAC and SOD en-
zyme activity while CAT, lipid peroxidation and reduced-GSH were not
significantly altered (p < 0.05) in comparison with the diabetic con-
trol. Additionally, vindoline and glibenclamide administration in non-
diabetic rats also improved the activity of SOD and CAT significantly
when compared to the normal control group (p < 0.05).
3.4. Effects of vindoline or glibenclamide on the levels of triglycerides, TNF-
ɑ, IL-10 and IL-6
Fig. 2 shows the effect of vindoline administration on the levels of
inflammatory biomarkers and triglycerides. An increase in TNF-ɑ levels
was observed in the diabetic controls when compared to the normal
control group (p < 0.05). Subsequent treatment of T2DM rats with
vindoline led to a significant down regulation (p < 0.05) of TNF-ɑ
levels when compared to the diabetic controls. IL-10 and IL-6 levels in
diabetic groups treated with vindoline and glibenclamide were not
significantly different from diabetic and normal control groups
(p < 0.05).
In this study, a marked reduction of serum triglycerides in T2DM
treated rats was noted in comparison with the diabetic controls
(p < 0.05). In addition, the serum triglycerides in the diabetic group
treated with vindoline and glibenclamide were restored to near normal
levels with no significant differences to normal controls (p < 0.05).
3.5. Effect of vindoline or glibenclamide on the histological architecture of
the hepatic tissue
Histological assessment of the liver sections of experimental groups
revealed the protective effect of vindoline against T2DM-induced tissue
damage. As indicated in Table 3 and Fig. 3; all the non-diabetic groups
showed normal liver architecture. Induction of diabetes resulted in
hepatocellular damage especially in the areas around the central vein,
where the cells showed signs of degeneration. However, treatment of
the diabetic groups with vindoline or glibenclamide resulted in mini-
mised tissue damage according to the histopathological scoring pre-
sented in Table 3. Central vein congestion accompanied by sinusoidal
congestion was prominent in the diabetic control group (Fig. 3 (D)) but
minimal in the vindoline treated diabetic group as shown in Fig. 3.
Dilation and disruption of normal sinusoidal architecture were evident
in the diabetic control group and in the diabetic group treated with
glibenclamide (arrows in Fig. 3D & F). Moderate infiltration of in-
flammatory cells was observed in the three diabetic groups.
3.5.1. Histological examination of the pancreas
Effect of vindoline or glibenclamide on the histological architecture
of the pancreatic tissue is shown Fig. 4. Plate A, B and C represents
normal pancreas with intact islets tissue with no visible signs of injury.
The diabetic untreated controls had small islets with vacuolated cells as
indicated in plate D1 below. The diabetic rats that were treated with
vindoline (plate E) had islets that were larger in size with minimum
destruction when compared to the diabetic controls. Administration of
glibenclamide to diabetic rats resulted in minimum pancreatic tissue
injury when compared to the diabetic controls (plate F).
3.5.2. Quantitative immunohistochemical findings
Fig. 5 illustrates the effect of vindoline and glibenclamide on the
expression of apoptotic markers in hepatic tissue of normal and T2DM
rats. Quantitative evaluation of images based on different nuclear
colour intensities was performed using imageJ software. Caspase 9 was
found to be significantly expressed in the diabetic control group at
(p < 0.05) when compared to all treatment groups. In addition; ad-
ministration of vindoline and glibenclamide in normal rats resulted in
increased expression of caspase 9 (p < 0.05) when compared to the
normal controls. With respect to the expression of BCL-2, treating
T2DM rats with vindoline or glibenclamide did not significantly alter
the expression of BCL-2 when compared to the diabetic control group
(p < 0.05). However the expression of BCL-2 in normal controls was
significantly increased when compared to the diabetic control, diabetic
Table 2
Effect of vindoline or glibenclamide treatment in T2DM-induced and normal rats.
Test NC NV NG DC DV DG
ALT 34.50 ± 5.13 40.88 ± 2.64b 27.88 ± 1.49b 161.6 ± 31.56a 94.43 ± 17.68ab 73.67 ± 13.33b
AST 88.13 ± 5.45 103.9 ± 9.05b 85.75 ± 8.13b 180.9 ± 37.35a 105.4 ± 18.98b 84.29 ± 13.61b
ALP 105.7 ± 9.14b 106.3 ± 7.73b 90.51 ± 5.33b 861.4 ± 132a 330.6 ± 51.6 ab 469.7 ± 64.2abc
LDH 15.36 ± 1.86b 19.18 ± 3.14b 19.75 ± 2.74b 78.81 ± 8.55 73.03 ± 8.85a 52.60 ± 9.5a
TP(g/L) 50.75 ± 5.55 61.16 ± 8.37ab 48.16 ± 3.1c 51.30 ± 7.84 43.85 ± 5.23c 39.48 ± 5.80a bc
Alb(g/L) 27.11 ± 2.65 31.95 ± 3.72a 27.40 ± 1.35 28.40 ± 3.07 25.85 ± 2.48c 22.58 ± 1.61abc
Glob 23.64 ± 1.06 29.21 ± 1.69 20.76 ± 1.45c 22.90 ± 2.05 18.00 ± 1.21c 16.90 ± 1.66c
Data represented as means ± SEM. a p < 0.05 vs normal control. b p < 0.05 vs diabetic control. C p < 0.05 vs normal rats treated with vindoline. NC: normal
control; NV: normal control treated with vindoline; NG: normal control treated with glibenclamide; DC: diabetic control; DV: diabetic treated with vindoline; DG:
diabetic treated with glibenclamide.
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groups treated with vindoline and glibenclamide (p < 0.05).
4. Discussion
The present study aimed to evaluate the effect of vindoline in
hepatotoxicity induced by T2DM conditions using glibenclamide as
reference drug. Uncontrolled hyperglycemia in DM is the hallmark of
free radical formation implicated in the modification of structures and
functions of macromolecules contributing to early development of
diabetic complications [33,34]. Antidiabetic therapy must therefore
Fig. 1. (A) Oxygen radical antioxidant capacity (ORAC), (B) Superoxide dismutase (SOD), (C) Catalase (CAT) measurements in groups, (D) Lipid peroxidation, (E)
Reduced glutathione. Data represented as means ± SEM. a p < 0.05 vs normal control. b p < 0.05 vs diabetic control. C P < 0.05 vs normal rats treated with
vindoline. NC: normal control; NV: normal control treated with vindoline; NG: normal control treated with glibenclamide; DC: diabetic control; DV: diabetic treated
with vindoline; DG: diabetic treated with glibenclamide.
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aim to maintain normoglycemia in addition to delay or prevention of
tissue injury [35]. Natural products are promising agents that could be
effective and safer in ameliorating diabetic complications [36]. Vin-
doline is an indole alkaloid derived from the leaves of C.roseus and has
been reported to stimulate the release of insulin from pancreatic beta
cells [37].
The results of this study showed a significant reduction in fasting
blood glucose levels in diabetic rats following treatment with vindoline.
It appeared that administration of glibenclamide in diabetic rats ex-
hibited lesser effects on fasting glucose level than vindoline which
suggests that vindoline may possess a better insulin secretory effect
than glibenclamide. We presumed that vindoline’s mechanism of action
was through stimulation of existing pancreatic β cells to secrete insulin.
Our findings are in agreement with the results reported by Yao et al
[37] who observed a marked reduction in blood glucose levels in T2DM
obese model. One of the side-effects of compounds that enhance insulin
excretory effect is hypoglycaemia. Based on our current findings; ad-
ministration of vindoline in non-diabetic rats did not induce hypogly-
caemia probably because the dosage administered was lower and tol-
erable [37,38].
Insulin deregulation is predictive of abnormal cofactors like hepatic
insulin resistance, hyperglycemia and β-cell dysfunction which mod-
ulate metabolic derangements [10]. Vindoline administration in T2DM
rats led to the elevation of insulin, the levels were higher than those
observed in the diabetic group treated with glibenclamide. Increased
insulin levels may have been due to its previously reported Kv2.1 in-
hibitory effect which reduces the voltage-dependent outward potassium
current resulting in insulin secretion by pancreatic β-cells [37]. Despite
the increased insulin level in the serum of both diabetic treated rats,
hyperglycemia was still present thus indicating resistance to the action
of insulin. In normal rats, vindoline administration did not stimulate
secretion of insulin, suggesting that vindoline may not have in-
sulotropic effects in normoglyecemic condition which is also in agree-
ment with Yao et al [37] findings.
It has been shown that DM patients suffer from severe weight loss as
a result of increased catabolism of fats and proteins in the skeletal
muscle in response to the deranged carbohydrate metabolism [39]. The
current study showed diminished body weight in all diabetic groups in
which vindoline and glibenclamide both failed to ameliorate weight
loss. Such result may be an indication that glycogenolysis, lipolysis and
proteolysis were still going on in order to compensate for the lack of
Fig. 2. Effects of vindoline or glibenclamide on the levels of inflammatory cytokines: TNF-ɑ, IL-10 and IL-6. Data represented as means ± SEM. a p < 0.05 vs
normal control. b p < 0.05 vs diabetic control. C P < 0.05 vs normal rats treated with vindoline. d p < 0.05 vs normal rats treated with glibenclamide. f p < 0.05
vs diabetic rats treated with glibenclamide. ns p < 0.5 non-significant change among all groups. NC: normal control; NV: normal control treated with vindoline; NG:
normal control treated with glibenclamide; DC: diabetic control; DV: diabetic treated with vindoline; DG: diabetic treated with glibenclamide.
Table 3
Histopathology score in hepatic tissue.
NC NV NG DC DV DG
Liver
Hepatocyte injury 0 0 0 2 1 1
Central vein congestion 0 0 0 2 1 1
Sinusoidal congestion 0 0 0 2 1 1
Sinusoidal dilation 0 0 0 2 0 1
Infiltration of inflammatory cells 0 0 0 1 1 1
Hepatic injury was scored as follows: o: absence of cell damage in> 80% of the
tissue; 1: damage< 30% of the tissue; 2: damage between 30–50% of tissue; 3:
necrosis> 50% of tissue. NC: normal control; NV: normal control treated with
vindoline; NG: normal control treated with glibenclamide; DC: diabetic control;
DV: diabetic treated with vindoline; DG: diabetic treated with glibenclamide.
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glucose in the cells [40]. Liver hypertrophy is a common observation in
diabetic animals attributed to increased free fatty acids pools in the
hepatocytes as a consequence of abnormal insulin metabolism [32]. All
diabetic groups in our study had increased relative liver weight when
compared to the normal groups. Treatment with vindoline and glib-
enclamide in diabetic rats did not significantly reverse liver
hypertrophy.
Hepatic enzymes which include amino transferases (AST and ALT)
and alkaline phosphatase (ALP) are the first line of markers used to
determine hepatic injury. In a state of hepatocellular damage, these
enzymes leak into the serum resulting in elevated levels. Elevated
serum transaminases are commonly observed in diabetics as a result of
Fig. 3. represents the haematoxylin and eosin stained liver sections (X100). A: normal control; B: normal control treated with vindoline; C: normal control treated
with glibenclamide; D: diabetic control; E: diabetic treated with vindoline; F: diabetic treated with glibenclamide. PT: portal tract; CV: central vein; S: sinusoids;
arrows indicate sinusoidal dilation and disordered arrangement of sinusoids.
Fig. 4. Histopathological changes in the pancreatic tissue of treated and non-treated diabetic and non-diabetic rats. Plate A (normal control) shows normal islets
tissue (IL) with well-defined borders, surrounded by the exocrine acinus cell (AC). Plates B (normal-treated with vindoline) and C (normal treated with glib-
enclamide) show normal islets (IL). Plate D (diabetic control) shows loss of the normal size and compactness of the islets, vacuolated degenerated islets (black
arrows). Treated islets with vindoline were smaller in size when compared to the normal but relatively larger in size than the diabetic controls. The Islets showed a
degree of vacuolation (arrows in Plate E) with slight regeneration. Glibenclamide treatment in diabetic rats (Plate F) showed few vacuolated islets and minimum loss
of islet architecture.
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Fig. 5. Pictorial and quantitative immunohistochemical representation of apoptotic markers of the liver sections labelled with anti-Bcl-2 and anti-caspase 9. Data
represented as means ± SEM. a p < 0.05 vs normal control. b p < 0.05 vs diabetic control. C p < 0.05 vs normal rats treated with vindoline. f p < 0.05 vs diabetic
rats treated with glibenclamide. Plate A–F represents caspase 9 marker intensities; Plate G–L represents Bcl-2 marker intensities. A/G= (NC): normal control; B/H=
(NV)= normal control treated with vindoline; C/I= (NG)= normal control treated with glibenclamide; D/J=DC=diabetic control; E/K=DV=diabetic treated
with vindoline; F/L=DG=diabetic treated with glibenclamide; arrows indicate high immunoreactive cells in anti-caspase 9 pictographs, arrow heads represents
negative immunoreactivity in anti-caspase 9 pictographs. In Bcl-2 pictographs; arrow heads indicate high immunoreactivity.
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functional disturbances of hepatocyte membranes [41–43]. Upon oral
administration of vindoline and glibenclamide in T2DM rats, the serum
levels of ALT, ALP and AST reduced significantly while LDH remained
unchanged when compared to the diabetic untreated group. These re-
sults may indicate comparable hepatoprotective effect of vindoline and
glibenclamide probably brought about by increased hepatocyte mem-
branal stability and hepatocellular regeneration. No significant altera-
tions were seen in normal rats treated with vindoline when compared to
the normal controls and normal rats treated with glibenclamide.
It is known that hyperglycaemia stimulates the breakdown of
structural proteins directly affecting the synthesis and secretion of vital
proteins like albumin [36,44]. Albumin is a major transporter protein
that carries analytes during various metabolic processes [45]. In the
present study, total protein concentration was lower in the diabetic
groups treated with vindoline (not significantly) and glibenclamide
(significantly) when compared to the untreated diabetic control. This
decrease could have been attributed to the increased binding of the
vindoline and glibenclamide components to serum albumins. This result
is in agreement with the results obtained by Iweala and Okeke [46] who
reported low levels of total protein in rats treated with C.roseus and
chlorpropamide. Unexpectedly, the total protein levels were high in the
diabetic controls without any significant difference when compared to
the normal controls. It is logical to argue that the high total protein
levels in the diabetic controls could have been falsely increased as a
result of dehydration due to polyuria [47,48]. In the vindoline treated
normal controls, a marked significant increase in the total protein was
seen when compared with the normal control and the glibenclamide
treated normal rats.
It is well established that persistent hyperglycemia is closely linked
to oxidative stress [49]. Oxidative stress is the underlying mechanism in
the development of diabetic complications via the excessive formation
of ROS and/ insufficient production of antioxidants [11,50]. In order to
evaluate if vindoline could decrease/ prevent oxidative damage, we
measured the oxygen radical absorbance capacity (ORAC), SOD and
CAT activities, lipid peroxidation and reduced-GSH levels in the liver
homogenates. The ORAC assay is performed to assess the ability of
biological samples to withstand the deleterious effects of excess free
radicals. The ability of the homogenates to scavenge oxygen radical was
augmented significantly to near normal in the T2DM rats treated with
vindoline more than the diabetic controls. Glibenclamide’s effect on
ORAC in diabetic rats was lower than that of vindoline suggesting that
vindoline may prevent cellular damage through its strong free radical
reduction capacity [50].
Superoxide dismutase, CAT and GSH are endogenous antioxidants
that work hand in hand to combat free radical toxicity in tissues. SOD is
an antioxidant enzyme responsible for the dismutation of the unstable
superoxide radicals into H2O2, while catalase catalyses the decom-
position of H2O2 into inert water and oxygen [45]. GSH is an anti-
oxidant defence molecule with powerful scavenging and detoxifying
potential against hydroxyl anion and oxygen radical [51]. Excessive
free radical build-up has been implicated in the initiation peroxidation
of cell membrane lipids. Peroxidation of membranal lipids destroys the
structural and functional integrity of the cell causing faulty perme-
ability which is harmful to cellular organelles [52].
In our findings; we observed obvious decrease in the activities of
these enzymes as well as in the level of GSH in the diabetic controls.
Interestingly, administration of vindoline and glibenclamide in diabetic
rats significantly improved the hepatic antioxidant status as evidenced
by elevated activities of SOD thus increasing protection against oxida-
tive injury. The same increase was observed in non-diabetic groups that
received glibenclamide and vindoline in comparison with the non-
treated controls. On the other hand; CAT activity and reduced-GSH
level in the vindoline treated diabetic group increased but not sig-
nificantly when compared to the diabetic controls and diabetic-glib-
enclamide treated group. Treatment of diabetic rats with glibenclamide
or vindoline did not significantly reduce the formation of by-products of
lipid peroxidation suggesting that their antioxidant effect only boosts
the first line of free radical defence antioxidants [52]. The antioxidant
effect exhibited by vindoline in this study shows an alternative ther-
apeutic effect of vindoline that could be useful in the treatment of
diabetes mellitus [49,53].
Various studies have indicated the important role inflammation
plays in the pathogenesis of insulin resistance, T2DM and its compli-
cations [54]. Inflammation is an adaptive response elicited by the body
following tissue injury in attempts to reverse injury [55]. The increased
release of inflammatory cytokines such as TNF-a, IL-6 and decreased
production of IL-10 in DM has been documented in diabetic models
[34]. We observed that the levels of IL-10-an anti-inflammatory cyto-
kine were significantly higher in the normal rats treated with vindoline
or glibenclamide when compared to the diabetic group treated with
glibenclamide. Vindoline administration in diabetic rats did not sig-
nificantly affect the levels of IL-10.
Depending on the tissue and metabolic state; IL-6 exists as both a
pro and anti-inflammatory cytokine [56]. According to our results, IL-6
levels in the hepatic homogenates were decreased in diabetic rats
treated with vindoline and glibenclamide although the results were not
significant when compared to the diabetic control. This result may in-
dicate that vindoline and glibenclamide could possibly safeguard the
hepatic tissue by suppressing the release of IL-6 by kupffer cells in
hyperglycaemic milleu. Due to the complexity of IL-6 metabolism, in
the non-diabetic groups’ IL-6 levels were not significantly different from
the diabetic control. This finding in the normal rats may be due to the
beneficial roles (anti-inflammatory) exerted by IL-6 [57]. A positive
correlation between TNF-ɑ and hepatic injury in diabetes has been
documented mainly because TNF-ɑ promotes insulin resistance that
leads to severe hyperglycemia and finally oxidative injury [58]. As-
sessment of TNF-ɑ demonstrated elevated levels in the diabetic control
group while, oral administration of vindoline evidently decreased TNF-
ɑ levels. This result suggests better potential immunomodulatory effect
of vindoline in comparison to glibenclamide which may be of ther-
apeutic relevance in preventing and/ retarding the onset of hepatic
tissue injury elicited by adverse inflammatory responses [59].
Abnormal fatty acid metabolism in diabetes mellitus is associated
with hypertriglyceridemia which is a risk factor for the development of
cardiovascular related diseases (CVDs) and NAFLD [60,61]. Lipoprotein
lipase is an enzyme that normally acts by hydrolysing triglycerides in
the presence of insulin. However in DM, its activation is denied due to
insulin deficiency resulting in hypertriglyceridemia [61,62]. Based on
our results, it is evident that treatment of diabetic rats with vindoline
decreased serum triglyceride levels when compared to the diabetic
controls. Vindoline and glibenclamide administration in T2DM rats
restored the triglyceride levels to near normal levels as the non-diabetic
controls. The reduction of the serum triglycerides in the diabetic treated
groups may have been due the increased activity of lipoprotein lipase
thus increasing the hydrolysis of triglycerides [40]. This observation
implies that vindoline may reduce the cardiovascular and NAFLD risks
associated with diabetes [63].
Our histopathological findings revealed that induction of T2DM
resulted in hepatic tissue damage which was confirmed by changes in
the tissue architecture. Liver section in diabetic rats demonstrated se-
vere mild leukocyte infiltration, central vein congestion, sinusoidal
dilation and congestion and hepatocyte vaculoation. These findings
were in agreement with the findings of Aldahmash et al [64] who re-
ported similar changes in DM mice. Administration of vindoline showed
appreciable improvements to these abnormal alterations revealed by
close to normal sinusoidal pattern and reduced congestion of the central
vein. Administration of glibenclamide in diabetic rats could not reverse
the dilation of sinusoids, which indicated vindoline’s more robust effect
in restoring diabetic liver pathology. Consequently, it was clearly ob-
served that induction of STZ in conjunction with the 10% fructose
water resulted in the destruction of insulin secreting β cells of the
pancreas as shown in Fig. 4 in plate D1 and D2. The pancreas of
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vindoline treated rats showed improvement in the size and islet mor-
phology when compared to the diabetic control and the diabetic-glib-
enclamide treated groups. Our results largely highlight vindoline may
not only stimulate insulin secretion but also protect the intact func-
tional β cells from STZ-induced destruction [37].
Oxidative stress together with adverse cytokine responses elicit the
activation of apoptosis in biological systems [65]. Bcl-2 is an important
protein that regulates apoptosis by preventing cell death [66]. Ac-
cording to the hepatic immunohistochemical reports, there was down-
regulation of Bcl-2 protein expression in the diabetic control rats. Oral
administration of vindoline in diabetic rats did not significantly in-
crease the expression of Bcl-2 when compared to the diabetic control
group. However, there was a marked downregulation of caspase 9 in
the hepatic tissue of diabetic rats treated with vindoline when com-
pared to the diabetic controls. Unlike Bcl-2, caspase 9 is a pro-apoptotic
protein which activates executioner-caspase 3 thus decreasing survival
chances of the cell. Enhanced expression of caspase 9 in diabetic control
rats in this study could indicate failed control of apoptosis in the mi-
tochondrial pathway [65,67]. Therefore, vindoline may be a valuable
therapeutic approach in the prevention of hepatic cell death in diabetes
mellitus.
5. Conclusion
In conclusion, our experimental findings suggest that vindoline as a
plant-derived product may be of great relevance in the treatment of
diabetes mellitus and its complications owing to its anti-hyperglycemic,
antihyperlipidemic, anti-inflammatory and antioxidant activities.
Further experimental studies are recommended to improve vindoline’s
delivery and absorption so as to increase its therapeutic effect.
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